Zandelisib - 半岛电竞官方网址

您好，欢迎来到半岛游戏平台官网入口网址设备网！ [登录] [免费注册]

立即咨询

Zandelisib

本半岛bd体育手机客户端不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

1401436-95-0

包装与价格：

半岛bd体育手机客户端介绍

Zandelisib (ME-401) 是一种 PI3K 抑制剂，选择性抑制 p110δ 的 IC50 值为 3.5 nM，详细信息请参考专利文献 WO2019183226 A1 中的化合物 1。Zandelisib 具有抗肿瘤作用。

Cas No.	1401436-95-0
别名	ME-401; PWT-143
分子式	C₃₁H₃₈F₂N₈O
分子量	576.68
溶解度	DMSO : 33.33 mg/mL (57.80 mM; ultrasonic and warming and adjust pH to 3 with HCl and heat to 60°C)
储存条件	Store at -20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request
半岛bd体育手机客户端描述	Zandelisib (ME-401) is a phosphatidylinositol 3-kinase (PI3K) inhibitor extracted from patent WO2019183226 A1, Compound Example 1. Zandelisib selectively inhibits p110δ with an IC50 of 3.5 nM. Zandelisib functions as an antineoplastic[1][2]. Zandelisib inhibits PI3Ks with IC50s of 4, 976 nM, 605 nM, 817 nM and 3.5 nM for p110α, p110β, p110γ and p110δ, respectivey[1]. [1]. Daniel P. Gold, et al. Combination therapy. WO2019183226A1. [2]. David Brown, et al. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases. WO2014055647A1.